While IL-1 inhibitors (anti-IL-1ß antibody or soluble type I IL-1 receptor) have modest effect in RA, it would be of interest to develop biological agents that block both IL-17 and IL-1 (69). This evidence concerns the gene IL1A and rheumatoid arthritis.